Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Adaptimmune Ther Ads (ADAP)

Adaptimmune Ther Ads (ADAP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,273,767
  • Shares Outstanding, K 130,109
  • Annual Sales, $ 1,120 K
  • Annual Income, $ -137,170 K
  • 60-Month Beta 2.41
  • Price/Sales 1,158.46
  • Price/Cash Flow N/A
  • Price/Book 6.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.24
  • Number of Estimates 3
  • High Estimate -0.23
  • Low Estimate -0.25
  • Prior Year -0.42
  • Growth Rate Est. (year over year) +42.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.85 +10.62%
on 06/15/20
12.12 -19.22%
on 06/03/20
-2.31 (-19.09%)
since 06/02/20
3-Month
2.57 +280.93%
on 04/03/20
13.40 -26.94%
on 06/01/20
+6.92 (+241.11%)
since 04/02/20
52-Week
0.71 +1,280.82%
on 11/15/19
13.40 -26.94%
on 06/01/20
+5.98 (+156.96%)
since 07/02/19

Most Recent Stories

More News
Growth Investing Leads in 1H: 5 Top ETFs & Stocks

Growth investing took a lead so far this year courtesy of massive money flowing into the economy.

NVAX : 81.64 (+2.43%)
NLS : 9.40 (+0.11%)
IWD : 113.05 (+0.51%)
ADAP : 9.79 (-2.00%)
IZEA : 1.1200 (-0.88%)
VUG : 205.27 (+0.42%)
JKE : 239.33 (+0.52%)
IWF : 195.56 (+0.47%)
MGK : 166.31 (+0.48%)
IWY : 108.74 (+0.47%)
VERI : 15.63 (-4.93%)
JKH : 297.84 (+0.38%)
Adaptimmune Therapeutics plc (ADAP) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Adaptimmune Therapeutics plc (ADAP).

ADAP : 9.79 (-2.00%)
How Adaptimmune Therapeutics (ADAP) Stock Stands Out in a Strong Industry

Adaptimmune Therapeutics (ADAP) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

ADAP : 9.79 (-2.00%)
Worried About a Weak Dollar? Here's How to Trade & Win

The ultra-easy Fed policy and widening U.S. deficit are likely to keep the greenback subdued in this coming days.

AAPL : 364.11 (unch)
BHP : 50.07 (+1.25%)
TXN : 125.81 (+0.81%)
PG : 120.88 (+0.75%)
YUM : 86.56 (+0.13%)
NEM : 60.96 (-0.65%)
FXE : 106.04 (-0.10%)
GMO : 0.2152 (+6.38%)
UUP : 26.28 (+0.08%)
ADAP : 9.79 (-2.00%)
UDN : 20.25 (-0.20%)
TLND : 36.75 (+2.37%)
ADNT : 16.54 (+3.31%)
MYOV : 20.03 (-0.60%)
WPM : 43.29 (-0.98%)
Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares

Adaptimmune Therapeutics plc ("Adaptimmune")(Nasdaq: ADAP), a leader in cell therapy to treat cancer, today announced the closing of its previously announced underwritten public offering of its American...

ADAP : 9.79 (-2.00%)
Are Options Traders Betting on a Big Move in Adaptimmune Therapeutics (ADAP) Stock?

Investors need to pay close attention to Adaptimmune Therapeutics (ADAP) stock based on the movements in the options market lately.

ADAP : 9.79 (-2.00%)
Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares

Adaptimmune Therapeutics plc ("Adaptimmune")(Nasdaq: ADAP), a leader in cell therapy to treat cancer, today announced the pricing of an underwritten public offering of 20,500,000 of its American Depositary...

ADAP : 9.79 (-2.00%)
Company News for June 1, 2020

Companies in the news are: ADAP, BIG, YAMHF, CGNX

BIG : 40.37 (-1.03%)
CGNX : 60.42 (+2.32%)
ADAP : 9.79 (-2.00%)
YAMHF : 15.8000 (+1.54%)
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares

Adaptimmune Therapeutics plc ("Adaptimmune")(Nasdaq: ADAP), a leader in cell therapy to treat cancer, today announced that it intends to offer and sell 12,500,000 American Depositary Shares ("ADSs") in...

ADAP : 9.79 (-2.00%)
Thinking about buying stock in Adaptimmune Therapeutics, MEI Pharma, Dynavax Technologies, AIM ImmunoTech, or Meridian Bioscience?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADAP, MEIP, DVAX, AIM, and VIVO.

ADAP : 9.79 (-2.00%)
AIM : 2.43 (-0.41%)
DVAX : 8.67 (+4.33%)
MEIP : 3.49 (-18.27%)
VIVO : 23.79 (+4.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ADAP with:

Business Summary

Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom.

See More

Key Turning Points

2nd Resistance Point 10.59
1st Resistance Point 10.19
Last Price 9.79
1st Support Level 9.39
2nd Support Level 8.99

See More

52-Week High 13.40
Last Price 9.79
Fibonacci 61.8% 8.55
Fibonacci 50% 7.05
Fibonacci 38.2% 5.56
52-Week Low 0.71

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar